Skip to main content
Home
  • English
  • العربية
  • SUPPORT
  • Log in
  • JOIN EXINITY
  • Markets
    • Markets

    Explore global financial markets

    Individual stocks
    • Stocks
    • Stock CFDs
    Forex and commodities
    • Forex pairs
    • Commodities
    Indices
    • Indices
    • Currency indices
  • Ways to trade
    • Ways to trade

    Explore our services at a glance

    • Exinity World

    Get pure investing simplicity and build a global portfolio from just $20

    • Exinity Trader

    Been trading for a while?
    Say hello to Trader

    • Exinity Trader Pro

    Pro, meet pro.
    The service for experienced traders

  • Edge
    Edge

    The markets are full of opportunity, but you won’t find it by accident. Edge puts useful and jargon-free insight at your fingertips.

    Edge library
    • Understanding the markets
    • Analysis and forecasting
    • Understanding risk and returns
    • Learning from experience
    Trading ideas
    • What our experts say
    • Meet our experts
  • About

What our experts say

Stock of the week: Citigroup stands out as we start the new year

Exinity
Research
04.01 @ 10:13 GMT
Exinity

US stock markets including the Dow Jones and the S&P 500 rose to fresh records at the start of this week as the market put new money to work on the first trading day of 2022. Market activity was brisk, the Nasdaq outperformed the other two major US indices, rising more than 1%, boosted by Tesla’s 13.5% jump after record quarterly car deliveries. Momentum is strong in risk assets right now, and history is on your side. According to Bank of America analysts, stocks have risen in the first trading week of January for 11 of the last 13 years, and we expect this to continue as we progress through the week.

Omicron’s mild symptoms leave markets to enjoy the new year

The twin concerns that spooked markets at the end of last year: The Omicron Covid variant and inflation and Fed rate rise fears have not had lasting effects. Even though Omicron case rates are running wild across the world, the medical data so far suggests that this variant is milder and thus, markets have weighed up that the risk this variant poses to economic growth is not of great concern. We believe that with each new wave of Covid, and there will be further waves this year, financial markets are able to get over them faster, and we expect this to continue to happen. Inflation fears and the timing of the first Fed rate hike remains a top priority for traders, however, with most economies open and ready for business there are signs that investors are beginning to see potential US interest rate increases as a good thing as it suggests economic strength. This is the positive backdrop as we start the trading week, and it is the backbone of why we have chosen the current stock of the week.

Why Citi is our pick this week

US banks have been one of our hot sectors for a few months now, as we believe that they will continue to do well in an inflationary environment and when the Fed starts hiking interest rates. The start of the year has seen short-term US Treasury yields surge, the 2-year yield is now 0.77%, the highest level since January 2020, as the market starts to price in the prospect of a Fed rate hike sooner than expected. According to the CME Fedwatch tool, there is now a 61.3% chance of rates to rise from 0-0.25% to 0.25-0.50% at the March meeting, which is only two meetings’ away. This is a huge shift and should support stocks that tend to do well when interest rates are on the up. This is the reason why we like Citigroup. Firstly, it’s a retail bank at heart and will benefit from the rising profit margins from mortgages when rates are rising. We would also note that long-term Treasury yields are also rising, with the 30-year yield back above 2%. Likewise, the US economy has remained open through the latest wave of Covid, which supports economic growth this quarter, a strong economy that is free from Covid disruption is also good news for retail banks like Citi that lend to individuals and businesses.

Another reason why we like Citigroup is because of its fundamentals. It received an upgraded buy rating from Bank of America analysts this week, who have a $100 stock price target on Citigroup, it is currently trading just above $63. Its current share price is well below tangible book value, and it has some compelling businesses that should attract institutional money as we move through January. Its corporate investment bank is another attractive asset, along with its transaction services business, which add to the lustre of owning Citi’s stock in our view.

More reasons to choose Citigroup

Some of you may be worried that you missed the boat, after all Citi’s stock price jumped more than 4% on Monday. However, we are not concerned by this as Citi’s share price is looking like a bargain compared to other US banks, as you can see in the chart below. We not only like Citi because of its compelling businesses that should do well in the current environment, but also because the market tends to favour stocks that have underperformed at the start of a new year. On trading floors, they call this ‘shopping the salvage yard’, and we have seen it in other sectors at the start of this week too, including airlines, cruise operators and casino stocks. The chart below highlights how Citi has underperformed the other major US banks in the past year. In an environment where risk appetite is high, we should see Citi play catch up. We also like when rival banks recommend each other, so the fact that Citi has been upgraded by BOA is another reason to like this stock at the start of the new year!

A word on our 2022 pharma pick

Before we end, we also wanted to update you on one of our picks for 2022, Pfizer. We mentioned that it was poised to continue to do well from its Covid franchise as the pandemic continues to develop in its third year. At the start of this week the pharma sector has underperformed, as the market ditched defensive stocks and went on a risk spending spree. However, after the likes of Moderna and BioNtech fell some 7% and 10% respectively on Monday, Pfizer’s shares were down only 4%, which is a sign that our trade idea for 2022 is currently working, and Pfizer should outperform other pharma stocks this year.

Chart 1:

Disclaimer: This material is comprised of personal opinions and ideas. It should not be construed as an investment recommendation or a solicitation for any transaction. It does not imply any obligation to purchase investment services, nor does it guarantee or predict future performance. Exinity, its affiliates, agents, directors, officers or employees do not guarantee the accuracy, validity, timeliness or completeness of any information or data made available and assume no liability for any loss arising from any investment based on the same.

Ready to jump into the markets?

Choose your Exinity experience and create your account in minutes

JOIN EXINITY
  •  
  •  
  •  
  •  
Home
  • About us
    • Exinity Group
    • Careers
    • Company news
    • Meet our experts
  • Useful links
    • Trading platforms
    • Trading tools
    • Trading hours
  • Support
    • FAQ
    • Contact us

The services on the Website are provided by Exinity Limited (exinity.com), regulated and licensed by the Financial Services Commission of the republic of Mauritius with an Investment Dealer License bearing license number C113012295.

Card transactions are processed via Exinity Services Limited (EU merchant company), a company incorporated in the Republic of Cyprus with company number ΗΕ 400404, registered office at 64 Agiou Georgiou Makri, Anna Maria Lena Court, Office 201, 6037, Larnaca, Cyprus and regulated by the laws of Cyprus. Address for cardholder correspondence: [email protected] Business location address: 35 Lamprou Konstantara, Kato Polemidia, 4156, Limassol, Cyprus.

Exinity ME Ltd is registered under the Laws of the Abu Dhabi Global Market (“ADGM”), with registered offices at 16-104, 16 Floor, Al Khatem Tower, ADGM Square, Al Maryah Island, Abu Dhabi, UAE. It is regulated by the Financial Services Regulatory Authority (“FSRA”), Financial Services Permission Number 200015 and is a duly licensed Category 3A Firm authorized to provide financial products and services to persons who meet the qualifying criteria of a Professional Client as defined by the FSRA rules.

Risk Warning: Trading Forex and Leveraged Financial Instruments involves significant risk and can result in the loss of your invested capital. You should not invest more than you can afford to lose and should ensure that you fully understand the risks involved. Trading leveraged products may not be suitable for all investors. Trading non-leveraged products such as stocks also involves risk as the value of a stock can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results. Before trading, please take into consideration your level of experience, investment objectives and seek independent financial advice if necessary. It is the responsibility of the Client to ascertain whether he/she is permitted to use the services of the Exinity brand based on the legal requirements in his/her country of residence. Please read Exinity’s full Risk Disclosure.

Regional restrictions: The Exinity brand does not provide services to residents of the USA, Japan, Canada, Mauritius, Haiti, Hong Kong, Suriname, the Democratic People's Republic of Korea, Puerto Rico, Cuba, Quebec, Syria, Iran, Iraq and the Occupied Area of Cyprus.

© 2021 Exinity

Terms and agreements   |   Privacy   |   Cookies